Foresee Pharmaceuticals, a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange has announced that the topline results of FP-001 LMIS (Leuprolide Mesylate Injectable Suspension) 25 mg phase 3 clinical trial, an open-label, single-arm study in subjects with Prostate Carcinoma. LMIS 25 mg is a 3-month depot injection. The primary efficacy end point was achieved in 97.9% of subjects.